Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells - ScienceDirect
Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design | PLOS ONE
New Strategies for Targeting CD38 in Multiple Myeloma Take Root
Efficiency and side effects of anti-CD38 CAR T cells in an adult patient with relapsed B-ALL after failure of bi-specific CD19/CD22 CAR T cell treatment | Cellular & Molecular Immunology
Strong antitumor activity of anti-CD38 CAR T cells in an MM model. A:... | Download Scientific Diagram
IJMS | Free Full-Text | Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma
CAR T-cell therapy in multiple myeloma: more room for improvement | Blood Cancer Journal
Driving Out Chronic Lymphocytic Leukemia With CAR T Cells - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy
Construction of anti-CD38 CAR T cells and its expression. A: Schematic... | Download Scientific Diagram
CD38 CAR-T Cell Therapy May Be Promising for Patients With Multiple Myeloma - Hematology Advisor
Targeting CD38/CD3 in the immunotherapy of Multiple Myeloma
Pan-heme CAR: Anti-CD38 CAR T cells for myeloid, lymphoid and plasma cell malignancies | Leukemia and Lymphoma Society
Lytic Capacity of Lower Affinity CD38-CAR T Cells toward Multiple... | Download Scientific Diagram
Current research on anti-CD38 CAR T-cell therapies - YouTube
CD38: An important regulator of T cell function - ScienceDirect
Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma | Haematologica
IJMS | Free Full-Text | Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance
High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma | Journal of Experimental & Clinical Cancer Research | Full Text
Cureus | Chimeric Antigen Receptor T Cell Therapy and Its Significance in Multiple Myeloma | Article
CAR T-cell therapy in multiple myeloma: more room for improvement | Blood Cancer Journal
Anti-CD38 CAR-T - Multiple Myeloma Clinical Trials
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma | Journal of Hematology & Oncology | Full Text
Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma | Haematologica
Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells | Molecular Pharmaceutics
